NCT07093476 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
| NCT ID | NCT07093476 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Celltrion |
| Condition | T2DM |
| Study Type | INTERVENTIONAL |
| Enrollment | 171 participants |
| Start Date | 2025-07-18 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 171 participants in total. It began in 2025-07-18 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
Eligibility Criteria
Inclusion Criteria: * Adults at the time of signing the Informed Consent Form (ICF) * Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study * Diagnosed with T2DM Exclusion Criteria: * Diagnosed with other types of diabetes than T2DM * History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy * Uncontrolled severe complications of diabetes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07093476 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying T2DM. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07093476 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 171 participants.
Is NCT07093476 currently recruiting?
Yes, NCT07093476 is actively recruiting participants. Contact the research team at sanghee.byun@celltrion.com for enrollment information.
Where is the NCT07093476 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07093476 clinical trial?
NCT07093476 is sponsored by Celltrion. The trial plans to enroll 171 participants.